Caplin Point Laboratories has informed that it enclosed press release regarding grant of final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution 0.3% (eye drops), to its Subsidiary Caplin Steriles.
The above information is a part of company’s filings submitted to BSE.